Literature DB >> 30481810

Severe Dry Eye With Combined Mechanisms is Involved in the Ocular Sequelae of SJS/TEN at the Chronic Stage.

Chie Sotozono1, Mayumi Ueta1, Norihiko Yokoi1.   

Abstract

Stevens-Johnson syndrome (SJS), and its more severe variant, toxic epidermal necrolysis (TEN), are life-threatening diseases of the skin and mucous membranes. After the acute-stage damage subsides, serious visual impairment and severe dry eye remains as ocular sequelae. At the acute stage, ocular complications occur in 77% of SJS/TEN patients. In cases with pseudomembranous formation and/or epithelial defects, the risk of ocular sequelae increases. Among 13 slit-lamp microscopy images that we obtained of SJS/TEN patients at the chronic stage, the loss of corneal epithelial stem cells and severe meibomian gland involvement were found to be the most common disorders. Severe dry eye in SJS includes three important mechanisms: (1) aqueous tear deficiency, (2) decreased wettability of corneal surface, and (3) increased evaporation. Dry eye severity in SJS patients is often underestimated when the meniscus is first observed, as the punctum is closed due to scarring or surgery. In SJS patients with severe dry eye, the dryness results in immense eye pain, and unstable tear film related to dry eye result in a change/loss of vision. For the treatment of dry eye in SJS, it is important to suppress chronic inflammation on the ocular surface, and 2% rebamipide ophthalmic solution reportedly helps to obtain ocular surface stabilization. Scleral contact lenses, as well as the newly developed limbal-rigid contact lenses, improve the patients' visual acuity and reduce symptoms related to severe dry eye. Further studies and new therapeutic methods are needed to more effectively treat dry eye in patients afflicted with SJS/TEN.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30481810     DOI: 10.1167/iovs.18-24019

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  Characteristics of meibomian gland dysfunction in patients with Stevens-Johnson syndrome.

Authors:  Tina Shrestha; Hyun Sik Moon; Won Choi; Hyeon Jeong Yoon; Yong Sok Ji; Mayumi Ueta; Kyung Chul Yoon
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

Review 2.  Vulvovaginal and ocular involvement and treatment in female patients with Stevens-Johnson syndrome and toxic epidermal necrolysis: A review.

Authors:  M Teresa Magone; Mary Maiberger; Janine Clayton; Helena Pasieka
Journal:  Int J Womens Dermatol       Date:  2021-09-02

Review 3.  Differential expression of tear film cytokines in Stevens-Johnson syndrome patients and comparative review of literature.

Authors:  Madhuri Amulya Koduri; Deeksha Prasad; Shriya Upadhyaya; Jilu Jaffet; Swapna S Shanbhag; Sayan Basu; Vivek Singh
Journal:  Sci Rep       Date:  2021-09-16       Impact factor: 4.379

Review 4.  Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN).

Authors:  E C Kuijper; L E French; C P Tensen; M H Vermeer; J N Bouwes Bavinck
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-05-15       Impact factor: 6.166

Review 5.  Management of ocular involvement in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: french national audit of practices, literature review, and consensus agreement.

Authors:  D Thorel; S Ingen-Housz-Oro; G Royer; A Delcampe; N Bellon; C Bodemer; A Welfringer-Morin; D Bremond-Gignac; M P Robert; M Tauber; F Malecaze; O Dereure; V Daien; A Colin; C Bernier; C Couret; B Vabres; F Tetart; B Milpied; T Cornut; B Ben Said; C Burillon; N Cordel; L Beral; N de Prost; P Wolkenstein; M Muraine; J Gueudry
Journal:  Orphanet J Rare Dis       Date:  2020-09-22       Impact factor: 4.123

Review 6.  Acute and Chronic Management of Ocular Disease in Stevens Johnson Syndrome/Toxic Epidermal Necrolysis in the USA.

Authors:  Derek Metcalfe; Omer Iqbal; James Chodosh; Charles S Bouchard; Hajirah N Saeed
Journal:  Front Med (Lausanne)       Date:  2021-07-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.